Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Drug Metabolism & Disposition
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Drug Metabolism & Disposition

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit dmd on Facebook
  • Follow dmd on Twitter
  • Follow ASPET on LinkedIn
Research ArticleArticle

Metabolism and Disposition of Vatalanib (PTK787/ZK-222584) in Cancer Patients

Lorenz M. Jost, Hans-Peter Gschwind, Tarja Jalava, Yongyu Wang, Clemens Guenther, Claire Souppart, Antje Rottmann, Karsten Denner, Felix Waldmeier, Gerhard Gross, Eric Masson and Dirk Laurent
Drug Metabolism and Disposition November 2006, 34 (11) 1817-1828; DOI: https://doi.org/10.1124/dmd.106.009944
Lorenz M. Jost
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hans-Peter Gschwind
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tarja Jalava
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yongyu Wang
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Clemens Guenther
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Claire Souppart
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Antje Rottmann
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Karsten Denner
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Felix Waldmeier
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gerhard Gross
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Eric Masson
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Dirk Laurent
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Abstract

Vatalanib (PTK787/ZK-222584) is a new oral antiangiogenic molecule that inhibits all known vascular endothelial growth factor receptors. Vatalanib is under investigation for the treatment of solid tumors. Disposition and biotransformation of vatalanib were studied in an open-label, single-center study in patients with advanced cancer. Seven patients were given a single oral 14C-radiolabeled dose of 1000 mg of vatalanib administered at steady state, obtained after 14 consecutive daily oral doses of 1000 mg of nonradiolabeled vatalanib. Plasma, urine, and feces were analyzed for radioactivity, vatalanib, and its metabolites. Metabolite patterns were determined by high-performance liquid chromatography coupled to radioactivity detection with off-line microplate solid scintillation counting and characterized by LC-MS. Vatalanib was well tolerated. The majority of adverse effects corresponded to common toxicity criteria grade 1 or 2. Two patients had stable disease for at least 7 months. Plasma Cmax values of 14C radioactivity (38.3 ± 26.0 μM; mean ± S.D., n = 7) and vatalanib (15.8 ± 9.5 μM) were reached after 2 and 1.5 h (median), respectively, indicating rapid onset of absorption. Terminal elimination half-lives in plasma were 23.4 ± 5.5 h for 14C radioactivity and 4.6 ± 1.1 h for vatalanib. Vatalanib cleared mainly through oxidative metabolism. Two pharmacologically inactive metabolites, CGP-84368/ZK-260120 [(4-chlorophenyl)-[4-(1-oxy-pyridin-4-yl-methyl)-phthalazin-1-yl]-amine] and NVP-AAW378/ZK-261557 [rac-4-[(4-chloro-phenyl)amino]-α-(1-oxido-4-pyridyl)phthalazine-1-methanol], having systemic exposure comparable to that of vatalanib, contributed mainly to the total systemic exposure. Vatalanib and its metabolites were excreted rapidly and mainly via the biliary-fecal route. Excretion of radioactivity was largely complete, with a radiocarbon recovery between 67% and 96% of dose within 7 days (42–74% in feces, 13–29% in urine).

Footnotes

  • This work was supported by Schering AG, Germany and Novartis Pharma AG, Switzerland.

  • Article, publication date, and citation information can be found at http://dmd.aspetjournals.org.

  • doi:10.1124/dmd.106.009944.

  • ABBREVIATIONS: VEGF, vascular endothelial growth factor; ADME, absorption, distribution, metabolism, and excretion; AE, adverse event; AUC, area under the concentration-time curve; HPLC, high-performance liquid chromatography; LC-MS, liquid chromatography coupled to mass spectrometry; LOQ, limit of quantification; LSC, liquid scintillation counting; PTK787/ZK-222584, vatalanib; radio-HPLC, HPLC coupled to radioactivity detection; ULN, upper limit of normal; VEGFR, vascular endothelial growth factor receptor; NVP-AAW378/ZK-261557, rac-4-[(4-chloro-phenyl)amino]-α-(1-oxido-4-pyridyl)phthalazine-1-methanol; CGP-84368/ZK-260120, (4-chloro-phenyl)-[4-(1-oxy-pyridin-4-yl-methyl)-phthalazin-1-yl]-amine; PTK787/ZK-226343, vatalanib (base), (4-chloro-phenyl)-(4-pyridin-4-yl-methyl-phthalazin-1-yl)-amine; CGP-85587/ZK-228353, [4-([1E,3E]-4-chloro-1-vinyl-penta-1,3-dienylamino)-phthalazin-1-yl]-pyridin-4-yl-methanol; CGP-85903/ZK-228354, ketopynalin, [4-(4-chloro-phenylamino)phthalazin-1-yl] (4-pyridyl) ketone; CGP-79469/ZK-260013, 4-(4-pyridin-4-yl-methyl-phthalazin-1-yl-amino)-phenol; ZK-260116, 2-chloro-5-(4-pyridin-4-ylmethyl-phthalazin-1-ylamino)-phenol.

    • Received February 23, 2006.
    • Accepted July 25, 2006.
  • The American Society for Pharmacology and Experimental Therapeutics
View Full Text

 

DMD articles become freely available 12 months after publication, and remain freely available for 5 years. 

Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page. 

 

  • Click here for information on institutional subscriptions.
  • Click here for information on individual ASPET membership.

 

Log in using your username and password

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.
PreviousNext
Back to top

In this issue

Drug Metabolism and Disposition: 34 (11)
Drug Metabolism and Disposition
Vol. 34, Issue 11
1 Nov 2006
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Back Matter (PDF)
  • Editorial Board (PDF)
  • Front Matter (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Drug Metabolism & Disposition article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Metabolism and Disposition of Vatalanib (PTK787/ZK-222584) in Cancer Patients
(Your Name) has forwarded a page to you from Drug Metabolism & Disposition
(Your Name) thought you would be interested in this article in Drug Metabolism & Disposition.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleArticle

Metabolism and Disposition of Vatalanib (PTK787/ZK-222584) in Cancer Patients

Lorenz M. Jost, Hans-Peter Gschwind, Tarja Jalava, Yongyu Wang, Clemens Guenther, Claire Souppart, Antje Rottmann, Karsten Denner, Felix Waldmeier, Gerhard Gross, Eric Masson and Dirk Laurent
Drug Metabolism and Disposition November 1, 2006, 34 (11) 1817-1828; DOI: https://doi.org/10.1124/dmd.106.009944

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Research ArticleArticle

Metabolism and Disposition of Vatalanib (PTK787/ZK-222584) in Cancer Patients

Lorenz M. Jost, Hans-Peter Gschwind, Tarja Jalava, Yongyu Wang, Clemens Guenther, Claire Souppart, Antje Rottmann, Karsten Denner, Felix Waldmeier, Gerhard Gross, Eric Masson and Dirk Laurent
Drug Metabolism and Disposition November 1, 2006, 34 (11) 1817-1828; DOI: https://doi.org/10.1124/dmd.106.009944
Reddit logo Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Materials and Methods
    • Results
    • Discussion
    • Conclusions
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • PK-PD studies of active ingredient in CH-I
  • IVIVE of aldehyde oxidase-mediated clearance
  • ALTBio Consortium developed for drug metabolism research.
Show more Articles

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About DMD
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Journal of Pharmacology and Experimental Therapeutics
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-009X (Online)

Copyright © 2023 by the American Society for Pharmacology and Experimental Therapeutics